Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 327

Similar articles for PubMed (Select 21051560)

1.

The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.

Leskelä S, Leandro-García LJ, Mendiola M, Barriuso J, Inglada-Pérez L, Muñoz I, Martínez-Delgado B, Redondo A, de Santiago J, Robledo M, Hardisson D, Rodríguez-Antona C.

Endocr Relat Cancer. 2010 Dec 21;18(1):85-95. doi: 10.1677/ERC-10-0148. Print 2011 Feb.

2.

SYK Blockade Enhances Paclitaxel Response in Ovarian Cancer.

[No authors listed]

Cancer Discov. 2015 Jun 25. [Epub ahead of print]

PMID:
26112670
3.

Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.

Zuberi M, Mir AB, Das J, Ahmad I, Javid J, Yadav P, Masroor M, Ahmad S, Ray PC, Saxena A.

Clin Transl Oncol. 2015 Jun 11. [Epub ahead of print]

PMID:
26063644
4.

MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603.

Villaruz LC, Huang G, Romkes M, Kirkwood JM, Buch SC, Nukui T, Flaherty KT, Lee SJ, Wilson MA, Nathanson KL, Benos PV, Tawbi HA.

Clin Epigenetics. 2015 Jun 4;7(1):58. doi: 10.1186/s13148-015-0092-2. eCollection 2015.

5.

Prognostic Value and Clinicopathology Significance of MicroRNA-200c Expression in Cancer: A Meta-Analysis.

Wu J, Fang Z, Xu J, Zhu W, Li Y, Yu Y.

PLoS One. 2015 Jun 2;10(6):e0128642. doi: 10.1371/journal.pone.0128642. eCollection 2015.

6.

Quantitative Proteomic Analysis of Mitochondria from Human Ovarian Cancer Cells and Their Paclitaxel-Resistant Sublines.

Chen M, Huang H, He H, Ying W, Liu X, Dai Z, Yin J, Mao N, Qian X, Pan L.

Cancer Sci. 2015 May 30. doi: 10.1111/cas.12710. [Epub ahead of print]

PMID:
26033570
7.

The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.

Brozovic A, Duran GE, Wang YC, Francisco EB, Sikic BI.

Mol Oncol. 2015 May 16. pii: S1574-7891(15)00113-1. doi: 10.1016/j.molonc.2015.04.015. [Epub ahead of print]

8.

Upregulation of microRNA-200a associates with tumor proliferation, CSCs phenotype and chemosensitivity in ovarian cancer.

Liu N, Zhong L, Zeng J, Zhang X, Yang Q, Liao D, Wang Y, Chen G, Wang Y.

Neoplasma. 2015 May 22. doi: 10.4149/neo_2015_066. [Epub ahead of print]

PMID:
25997962
9.

Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers.

Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W.

J Natl Cancer Inst. 2015 May 20;107(7). pii: djv108. doi: 10.1093/jnci/djv108. Print 2015 Jul.

PMID:
25995442
10.

Class III Beta-tubulin Expression in Non-small Cell Lung Cancer: A Predictive Factor for Paclitaxel Response.

Ohashi T, Yoshimasu T, Oura S, Kokawa Y, Kawago M, Hirai Y, Miyasaka M, Aoishi Y, Kiyoi M, Nishiguchi H, Honda M, Okamura Y.

Anticancer Res. 2015 May;35(5):2669-74.

PMID:
25964544
11.

Prognostic role of miR-200c in various malignancies: a systematic review and meta-analysis.

Zhang KC, Xi HQ, Cui JX, Shen WS, Li JY, Wei B, Chen L.

Int J Clin Exp Med. 2015 Feb 15;8(2):1931-43. eCollection 2015.

12.

Combined Influence of EGF+61G>A and TGFB+869T>C Functional Polymorphisms in Renal Cell Carcinoma Progression and Overall Survival: The Link to Plasma Circulating MiR-7 and MiR-221/222 Expression.

Teixeira AL, Dias F, Ferreira M, Gomes M, Santos JI, Lobo F, Maurício J, Machado JC, Medeiros R.

PLoS One. 2015 Apr 24;10(4):e0103258. doi: 10.1371/journal.pone.0103258. eCollection 2014.

13.

Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer.

Sun R, Liu Z, Wang L, Lv W, Liu J, Ding C, Yuan Y, Lei G, Xu C.

Tumour Biol. 2015 Apr 18. [Epub ahead of print]

PMID:
25894372
14.

CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.

Nymoen DA, Holth A, Hetland Falkenthal TE, Tropé CG, Davidson B.

Mol Cancer. 2015 Feb 18;14:44. doi: 10.1186/s12943-015-0317-1.

15.

Circulating miR-200c and miR-141 and outcomes in patients with breast cancer.

Antolín S, Calvo L, Blanco-Calvo M, Santiago MP, Lorenzo-Patiño MJ, Haz-Conde M, Santamarina I, Figueroa A, Antón-Aparicio LM, Valladares-Ayerbes M.

BMC Cancer. 2015 Apr 2;15:297. doi: 10.1186/s12885-015-1238-5.

16.

How microRNAs modify protein production.

Feig JL, Giles KM, Osman I, Franks AG Jr.

J Invest Dermatol. 2015 May;135(5):e32. doi: 10.1038/jid.2015.99. No abstract available.

PMID:
25882467
17.

MicroRNA signatures of platinum-resistance in ovarian cancer.

Ying HC, Xu HY, Lv J, Ying TS, Yang Q.

Eur J Gynaecol Oncol. 2015;36(1):16-20.

PMID:
25872328
18.

miR-150 is a factor of survival in prostate cancer patients.

Dezhong L, Xiaoyi Z, Xianlian L, Hongyan Z, Guohua Z, Bo S, Shenglei Z, Lian Z.

J BUON. 2015 Jan-Feb;20(1):173-9.

PMID:
25778313
19.

Prognostic role of tissue and circulating microRNA-200c in malignant tumors: a systematic review and meta-analysis.

Shao Y, Geng Y, Gu W, Huang J, Pei H, Jiang J.

Cell Physiol Biochem. 2015;35(3):1188-200. doi: 10.1159/000373943. Epub 2015 Feb 10.

PMID:
25766530
20.

Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients.

Bateman NW, Jaworski E, Ao W, Wang G, Litzi T, Dubil E, Marcus C, Conrads KA, Teng PN, Hood BL, Phippen NT, Vasicek LA, McGuire WP, Paz K, Sidransky D, Hamilton CA, Maxwell GL, Darcy KM, Conrads TP.

J Proteome Res. 2015 Apr 3;14(4):1900-10. doi: 10.1021/pr5012894. Epub 2015 Mar 19.

PMID:
25748058
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk